Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

(2019) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade

(2019) Guo-Liang Chew et al.   DEVELOPMENTAL CELL

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

(2018) Toni K Choueiri et al.   LANCET ONCOLOGY

The landscape of genomic alterations across childhood cancers

(2018) Susanne N. Gröbner et al.   NATURE

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

(2018) David F. McDermott et al.   NATURE MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics, treatment patterns and safety events from 4 cohorts of advanced or metastatic cancer patients based on health care claims data.

(2018) Leo Russo et al.   JOURNAL OF CLINICAL ONCOLOGY

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

(2017) Christopher R Heery et al.   LANCET ONCOLOGY

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

(2017) Helen Ha et al.   Theranostics

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Immunological properties of oxygen-transport proteins: hemoglobin, hemocyanin and hemerythrin

(2016) Christopher J. Coates et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

(2016) Toni K. Choueiri et al.   CLINICAL CANCER RESEARCH

Role of lipids in the metabolism and activation of immune cells

(2016) Merla J. Hubler et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations

(2016) Jennifer A. Oberg et al.   Genome Medicine

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

(2015) Thomas Powles et al.   Journal for ImmunoTherapy of Cancer

OptiType: precision HLA typing from next-generation sequencing data

(2014) András Szolek et al.   BIOINFORMATICS

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

(2014) T. K. Choueiri et al.   CLINICAL CANCER RESEARCH

The Genomic Landscape of Pediatric Ewing Sarcoma

(2014) B. D. Crompton et al.   Cancer Discovery

A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis

(2013) Massimo Masiero et al.   CANCER CELL

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

(2013) M. J. Brauer et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

DUX4 Differentially Regulates Transcriptomes of Human Rhabdomyosarcoma and Mouse C2C12 Cells

(2013) Vishakha Sharma et al.   PLoS One

Novel mutations target distinct subgroups of medulloblastoma

(2012) Giles Robinson et al.   NATURE

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy

(2011) Linda N. Geng et al.   DEVELOPMENTAL CELL

Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer

(2009) Christina L. Roland et al.   PLoS One

WGCNA: an R package for weighted correlation network analysis

(2008) Peter Langfelder et al.   BMC BIOINFORMATICS